Apixaban

Apixaban is an orally active, active site-targeting, highly potent and selective inhibitor of factor Xa (FXa), an essential component of the coagulation cascade. It functions by selectively binding to both free and clot-bound factor Xa, thereby inhibiting its activity and preventing the conversion of prothrombin to thrombin. This inhibition ultimately leads to the prevention of thrombin formation and subsequent blood clot formation. Apixaban achieves this by targeting the active site of factor Xa, interfering with its ability to interact with its substrates. By doing so, it effectively disrupts the coagulation process and impedes the formation of fibrin clots. This mechanism of action makes apixaban a promising candidate for research and development aimed at understanding and manipulating the coagulation cascade. In vivo, apixaban has antithrombotic efficacy in vivo in a rabbit model of venous thrombosis. Formulations containing apixaban have been used to prevent blood clot formation in patients with atrial fibrillation.